Premium
P3‐430: INFERIOR AND MEDIAL TEMPORAL TAU AND CORTICAL AMYLOID ARE ASSOCIATED WITH DAILY FUNCTIONAL IMPAIRMENT ACROSS THE AD SPECTRUM
Author(s) -
Halawa Omar A.,
Marshall Gad A.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1793
Subject(s) - entorhinal cortex , dementia , temporal lobe , psychology , pittsburgh compound b , alzheimer's disease , positron emission tomography , audiology , neuroscience , amyloid (mycology) , neuroimaging , neurofibrillary tangle , temporal cortex , medicine , hippocampus , cognitive impairment , pathology , cognition , senile plaques , disease , epilepsy
and a FLAIR sequence. All hemispheres underwent neuropathologic examination by a board-certified neuropathologist (Fig.1). Logistic regression with L1 penaltywas used for training and testing two classifiers. The first classifier (referred to as baseline) used whole brain WMH burden as the sole feature. The second classifier was based on a feature vector including regional WMH burden, magnetic susceptibility of subcortical gray matter, number of microbleeds, and demographics (age, sex, education). 10-fold cross validation was used to assess generalization performance. Results: According to the receiver operating characteristic (ROC) (Fig.2) and precisionrecall (PR) curves (Fig.3), the proposed classifier showed superior performance over the baseline classifier, for all thresholds (p1⁄40.068). Conclusions: The proposed classifier based on regional WMH burden, magnetic susceptibility, microbleeds and demographics, was shown to have superior performance for identifying older adults with arteriolar sclerosis compared to a classifier based only on whole brain WMH burden. We will soon be able to dramatically increase the sample size, include additional features, and test the classifier in-vivo. Successful completion of this work will bring forward a much-needed biomarker for arteriolar sclerosis for use in clinical trials.